Eras­ca delves fur­ther in­to RAS/MAPK with No­var­tis drug, prices $100M of­fer­ing

Af­ter re­ceiv­ing feed­back on piv­otal stud­ies from Eu­ro­pean reg­u­la­tors, but not yet the FDA, No­var­tis is out-li­cens­ing a pan-RAF in­hibitor go­ing af­ter tu­mors ex­cit­ed by the RAS/MAPK path­way.

To get the ex­clu­sive world­wide li­cense to the as­set, Eras­ca is pay­ing the Swiss Big Phar­ma $20 mil­lion up­front in cash and $80 mil­lion worth of shares. Eras­ca CEO Jonathan Lim told an­a­lysts Fri­day morn­ing that the process was “com­pet­i­tive,” im­ply­ing his biotech was far from the on­ly one at­tempt­ing to snag the drug from No­var­tis, which is go­ing through a re­or­ga­ni­za­tion and a fine-tun­ing to its pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER